Tivantinib

Drug Profile

Tivantinib

Alternative Names: ARQ-197

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ArQule
  • Developer ArQule; Daiichi Sankyo Company; Istituto Clinico Humanitas; Istituto Oncologico Veneto; Kyowa Hakko Kirin; National Cancer Institute (USA); National Institutes of Health (USA); SCRI Development Innovations
  • Class Antineoplastics; Pyrrolidinones; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatocellular carcinoma
  • Discontinued Colorectal cancer; Gastric cancer; Germ cell and embryonal neoplasms; Head and neck cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 06 Oct 2017 Discontinued - Phase-I for Hepatocellular carcinoma (Combination therapy) in USA (PO)
  • 06 Oct 2017 Discontinued - Phase-I for Hepatocellular carcinoma (Monotherapy, Second-line therapy or greater) in Italy, USA, Spain (PO)
  • 06 Oct 2017 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top